{"DataElement":{"publicId":"37","version":"3","preferredName":"Prior Growth Factor Received Ind-2","preferredDefinition":"the yes/no indicator to specify if the patient received any growth factor agents just prior to study entry.","longName":"PRIO_GFAC_RECD_IND-2","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2014048","version":"1","preferredName":"Prior Growth Factor Received","preferredDefinition":"information relating to the administration of growth factors to the patient.","longName":"PRIOR_GFAC_RECD","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2206436","version":"1","preferredName":"Prior Growth Factor","preferredDefinition":"Earlier in time or order.:Substances made by the body that function to regulate cell division and cell survival. Some growth factors are also produced in the laboratory and used in biological therapy.","longName":"C25629:C20424","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Growth Factor","conceptCode":"C20424","definition":"Growth Factors are extracellular signaling molecules (ligands) involved in control of target cell proliferation, cell survival, and cell differentiation. (NCI)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0428-F522-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2184327","version":"1","preferredName":"Received","preferredDefinition":"Received; taken, gotten, or acquired.","longName":"Received","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Receive","conceptCode":"C25639","definition":"To take, accept, or get something offered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB6C8AC6-1F66-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B318870A-C904-3702-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-31","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-31","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811835","version":"1","longName":"Melanoma","context":"CTEP"},{"publicId":"2811871","version":"1","longName":"Colorectal","context":"CTEP"},{"publicId":"2811831","version":"1","longName":"Breast","context":"CTEP"},{"publicId":"2811908","version":"1","longName":"Gynecologic","context":"CTEP"},{"publicId":"2811909","version":"1","longName":"Leukemia","context":"CTEP"},{"publicId":"2811950","version":"1","longName":"Multiple Myeloma","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"}]},{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"3303197","version":"1","longName":"Phase 1/Pilot Consortium","context":"COG"}]},{"publicId":"4254096","version":"1","longName":"Protocol Phase","context":"PBTC","ClassificationSchemeItems":[{"publicId":"10000103","version":"1","longName":"Phase I","context":"PBTC"},{"publicId":"4254119","version":"1","longName":"PBTC-042","context":"PBTC"}]}],"AlternateNames":[{"name":"PRIO_GFAC_RECD_IND-2","type":"USED_BY","context":"CTEP"},{"name":"PBTC","type":"USED_BY","context":"PBTC"},{"name":"PRIO_GFAC_RECD_IND-2","type":"USED_BY","context":"COG"},{"name":"ECOG-ACRIN","type":"USED_BY","context":"ECOG-ACRIN"}],"ReferenceDocuments":[{"name":"CRF Text","type":"Alternate Question Text","description":"Growth Factor Ind","url":null,"context":"CTEP"},{"name":"Did patient receive growth fa","type":"Preferred Question Text","description":"Did patient receive growth factors within 1 week of entry onto this study?","url":null,"context":"CTEP"},{"name":"COG_CRF_TEXT_1","type":"Alternate Question Text","description":"Prior hematopoietic growth factor agents received","url":null,"context":"CTEP"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Did patient receive growth factors that support platelet or white cell number or function within 7 days prior to study enrollment?","url":null,"context":"CTEP"},{"name":"PBTC_Text1","type":"Alternate Question Text","description":"Did patient receive all colony forming growth factors for more than 1 week and all long acting growth factors for more than 2 weeks prior to registration?","url":null,"context":"PBTC"},{"name":"PBTC_Text3","type":"Alternate Question Text","description":"Has patient received colony-stimulating factors < 1 week prior to enrollment (GCSF, GM CSF, erythropoietin)? Two weeks must have elapsed if patients received PEG formulations.","url":null,"context":"PBTC"},{"name":"PBTC_Text2, exclusion","type":"Alternate Question Text","description":"Has patient received colony-stimulating factors < 1 week prior to registration (GCSF, GM CSF, erythropoietin)?  Two weeks must have elapsed if patients received PEG formulations.","url":null,"context":"PBTC"},{"name":"ECOG CRF Text 1","type":"Alternate Question Text","description":"Did the patient receive growth factors?","url":null,"context":"ECOG-ACRIN"},{"name":"PBTC_Text2","type":"Alternate Question Text","description":"Has it been <=7 days since the last dose of growth factors?","url":null,"context":"PBTC"},{"name":"PBTC_Text4","type":"Alternate Question Text","description":"Patient is off all colony-stimulating growth factor(s) for at least 1 week prior to enrollment (i.e. filgrastim, sargramostim), and at least two weeks have elapsed if patients received PEG formulations?","url":null,"context":"PBTC"},{"name":"PBTC_Text5","type":"Alternate Question Text","description":"Patient is off all colony-stimulating growth factor(s) for at least 7 days prior to enrollment (i.e. filgrastim, sargramostim), and at least 14 days have elapsed if patients received PEG formulations?","url":null,"context":"PBTC"},{"name":"PBTC_Text6","type":"Alternate Question Text","description":"Patient is off all colony forming growth factor(s) for at least one week prior to enrollment (i.e. filgrastim, sargramostim and erythropoietin), and at least two weeks have elapsed if patient received  long acting growth factors?","url":null,"context":"PBTC"},{"name":"COG CRF Text 3","type":"Alternate Question Text","description":"Has it been more than 7 days since the last dose of growth factor prior to study enrollment?","url":null,"context":"COG"},{"name":"PBTC_Text7","type":"Alternate Question Text","description":"Is patient off all colony-stimulating growth factor(s) for at least 1 week prior to enrollment (i.e. filgrastim, sargramostim or erythropoietin), and at least 2 weeks have elapsed if patients received PEG formulations?","url":null,"context":"PBTC"},{"name":"PBTC_Text8","type":"Alternate Question Text","description":"Patient is off all colony-stimulating growth factor(s) for at least 7 days prior to enrollment (i.e. filgrastim, sargramostim or erythropoietin), and at least 14 days have elapsed if patients received PEG formulations?","url":null,"context":"PBTC"},{"name":"PBTC_Text9","type":"Alternate Question Text","description":"Patient is off all colony-stimulating growth factor(s) for at least 7 days prior to enrollment (e.g. filgrastim, sargramostim or erythropoietin), and at least 14 days have elapsed if patients received PEG formulations?","url":null,"context":"PBTC"},{"name":"PBTC_Text10","type":"Alternate Question Text","description":"Is patient off all colony-stimulating factor(s) (e.g. filgrastim, sargramostim or erythropoietin) for at least 1 week prior to enrollment, and at least 2 weeks have elapsed if patient received PEG formulations?","url":null,"context":"PBTC"},{"name":"COG CRF Text 4","type":"Alternate Question Text","description":"Have prior hematopoietic growth factor agents been received?","url":null,"context":"COG"},{"name":"ECOG-ACRIN - 1","type":"Alternate Question Text","description":"If the patient completed the baseline (T0) FDG-PET/CT prior to registration, did the patient use colony stimulating growth factors within 14 days prior to completing the T0 scan?","url":null,"context":"ECOG-ACRIN"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"B31A0A7A-4445-3A22-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-31","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-31","modifiedBy":"FINCHAMB","dateModified":"2023-03-10","changeDescription":"Replaced VD Prior Growth Factor Received Ind-2 [2196321v1.0] with VD ID#3506068 - Yes No Indicator   - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}